Bio-Rad Laboratories, Inc. (BIO.B)
| Market Cap | 17.76B |
| Revenue (ttm) | 2.29B |
| Net Income (ttm) | 3.52B |
| Shares Out | 5.09M |
| EPS (ttm) | 116.69 |
| PE Ratio | 5.19 |
| Forward PE | 51.02 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 13 |
| Last Price | $605.65 |
| Previous Close | $605.65 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 574.15 - 605.65 |
| Day's Volume | 0 |
| 52-Week Range | 324.07 - 642.05 |
News
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
The recent development will help Bio-Rad rake in increased top-line contributions from the Clinical Diagnostics business.
About BIO.B
Bio-Rad Laboratories develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are use... [Read more...]
| Industry Medical Devices | Founded 1952 |
| CEO Norman Schwartz | Employees 8,000 |
| Stock Exchange NYSE | Ticker Symbol BIO.B |